Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

NCT01628445 on ClinicalTrials.gov · last registry update 2016-01-21

Stopped early, having planned 52 participants. The sponsor logged completion for November 2015. Primary outcome, as filed: Change in A1c. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Manitoba
Sponsor type: Other
Enrollment: 52
Started: 2012-08
Primary completion: 2015-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in A1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.